Transactions involving the acquisition of FDA-regulated firms and/or the licensing of products present unique challenges during the due diligence process. This session focuses on best practices and real-life examples of pitfalls that make or break the deal as they relate to intellectual property issues, clinical research, and regulatory requirements including:
- Projecting the scope of exclusionary rights on the product
- How the “useful” life cycle of a patent impacts transaction value and associated risks
- Evaluating the risks associated with patent litigation with respect to small molecules and follow-on biologics
- Understanding the clinical research and development program – how to maximize potential for success
- What can go wrong with clinical trials and practical suggestions to ensure compliance
- Identifying critical aspects of FDA regulatory authority relative to a diligence review
- Determining regulatory pathways towards product approval
- Prospecting opportunities to increase product life cycles
Panelists include: Doug Carsten, Partner, Foley; Jeff Miller, VP, Regulatory Affairs and Quality Assurance, Icon Clinical Research; David Rosen, Co-Chair, Life Sciences Team, Foley.
Related Insights
17 December 2024
Events
Ready, Set, Govern: Integrating AI Governance into Corporate Compliance Programs
Natasha Allen (Partner, Silicon Valley) will be joining Compliance Week on their webinar, “Ready, Set, Govern: Integrating AI governance into Corporate Compliance Programs.
05 December 2024
Consumer Class Defense Counsel
Sixth Circuit: Reliance Can Bar Class Certification Even if Not Express Element of Consumer Statutory Claim
Courts routinely refuse to certify consumer class actions under Federal Rule of Civil Procedure 23(b)(3) based on the need for an individualized showing of the reliance element of a fraud or deceptive trade practices claim.
05 December 2024
Consumer Class Defense Counsel
Office of the Comptroller of the Currency Updates “Unfair or Deceptive Acts or Practices and Unfair, Deceptive, or Abusive Acts or Practices” Booklet
Financial institutions that are regulated and supervised by the Office of the Comptroller of the Currency (OCC) should know that the OCC has recently updated its booklet on Unfair or Deceptive Acts or Practices (UDAP) and Unfair, Deceptive, or Abusive Acts or Practices.